

LIFELINE BIOTECHNOLOGIES, INC.

2313 Hollyhill Lane
Denton, TX 76205

626.429.2780
carenlarsen@hotmail.com

Quarterly Report

For the period ending March 31, 2026 (the “Reporting Period”)

Outstanding Shares

The number of shares outstanding of our Common Stock was:

4,348,921,001 as of March 31, 2026 *(Current Reporting Period Date or More Recent Date)*

4,348,921,001 as of December 31, 2025 *(Most Recent Completed Fiscal Year End)*

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☒ No: ☐

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Change in Control

Indicate by check mark whether a Change in Control⁵ of the company has occurred during this reporting period:

Yes: ☐ No: ☒

⁵ “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Lifeline BioTechnologies, Inc.

Current State and Date of Incorporation or Registration: Nevada – November 6, 1981

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

N/A

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

N/A

List any company name change, stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

N/A

Address of the issuer's principal executive office:

2313 Hollyhill Lane, Denton, TX 76205

Address of the issuer's principal place of business:

☒ *Check if principal executive office and principal place of business are the same address:*

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☐ Yes: ☒ If Yes, provide additional details below:

On June 3, 2021 in the Clark County, Nevada District Court, Case A-21-835694-P (Department 29) was a petition for Appointment of Custodianship was filed by Acropolis Capital Partners. Ryan Ash, Acropolis, appointed Caren Currier on June 25, 2021 as interim CEO.

Settlement Agreement with Jim and Ann Holmes and related entities; as individuals and related entities including Carson Capital Management, Inc. and all other majority-controlled entities and/or trusts ("JAH") for \$20,000 was reached.

On May 2, 2024, there was a motion entered to terminate custodianship that was granted on July 1, 2024.

2) Security Information

Transfer Agent

Name: ClearTrust, LLC
Phone: 18132354490
Email: accounting@cleartrusttransfer.com
Address: 16540 Pointe Village Dr Ste 210 Lutz, FL 33558

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>LLBO</u>	
Exact title and class of securities outstanding:	<u>Common</u>	
CUSIP:	<u>53219E808</u>	
Par or stated value:	<u>0.001</u>	
Total shares authorized:	<u>4,950,000,000</u>	as of date: <u>March 31, 2026</u>
Total shares outstanding:	<u>4,348,921,001</u>	as of date: <u>March 31, 2026</u>
Total number of shareholders of record:	<u>993</u>	as of date: <u>March 31, 2026</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	<u>Preferred A</u>	
Par or stated value:	<u>.00001</u>	
Total shares authorized:	<u>5,000,000</u>	as of date: <u>March 31, 2026</u>
Total shares outstanding:	<u>4,950,000*</u>	as of date: <u>March 31, 2026</u>
Total number of shareholders of record:	<u>2</u>	as of date: <u>March 31, 2026</u>

*Per stock certificate copies located as no additional certificates were confirmed on disclosures through the period of December 31, 2019

Exact title and class of the security:	<u>Preferred B</u>	
Par or stated value:	<u>.00001</u>	
Total shares authorized:	<u>7,500,000</u>	as of date: <u>March 31, 2026</u>
Total shares outstanding:	<u>1,286,535</u>	as of date: <u>March 31, 2026</u>
Total number of shareholders of record:	<u>92</u>	as of date: <u>March 31, 2026</u>

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

Common Shares will have a 1:1 vote and no dividends

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Preferred Series A – Each share of Preferred Series A stock shall be entitled to 1000:1 votes on all matters. Series A and Common Stock holders shall vote together as a single class on all matter and dividends shall be the same as Common Shares.

Preferred Series B – Each share of Preferred Series B stock shall be entitled to 1:1 votes on all matters. Series B and Common Stock holders shall vote together as a single class on all matter and dividends shall be the same as Common Shares.

3. Describe any other material rights of common or preferred stockholders.

None

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

3) Issuance History

*The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.***

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance:</u> Date <u>12.31.21</u> Common: <u>3,348,921,001</u> Preferred: <u>6,236,535</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>01.24.24</u>	<u>New</u>	<u>500,000,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Acropolis Capital</u> <u>Ryan Ash</u>	<u>Servies</u>	<u>Restricted</u>	<u>144</u>
<u>01.24.24</u>	<u>New</u>	<u>500,000,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Caren Currier</u>	<u>Servies</u>	<u>Restricted</u>	<u>144</u>
_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
Shares Outstanding on Date of This Report: <u>Ending Balance:</u> Date <u>12.31.25</u> Common: <u>4,348,921,001</u> Preferred: <u>6,236,535</u>									

Example: A company with a fiscal year end of December 31st 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

☒ Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of	# Shares Converted to Date	# of Potential Shares to be	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)

				instrument to shares)		Issued Upon Conversion ⁶		

Total Outstanding Balance:

Total Shares:

Any additional material details, including footnotes to the table are below:

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

No Operations

B. List any subsidiaries, parent company, or affiliated companies.

None

C. Describe the issuers' principal products or services.

None

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

Officer allows use of her office at no charge

⁶ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

6) All Officers, Directors, and 5% Beneficial Owners of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, ≥ 5% beneficial owner)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Caren Currier	President/CEO	Denton, TX	500,000,000 4,700,000	Common Preferred A	11.497% 94.949%
Acropolis Capital – Ryan Ash	Custodian	Sheridan, WY	500,000,000	Common	11.497%

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

N/A

Accountant or Auditor

Name: TBD
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): _____
Discord: _____
LinkedIn: _____
Facebook: _____
[Other]: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: **Caren Currier**
Title: **President**
Relationship to Issuer: **Self**

B. The following financial statements were prepared in accordance with:

- ☐ IFRS
☒ U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Caren Currier
Title: President
Relationship to Issuer: Self

Describe the qualifications of the person or persons who prepared the financial statements:⁷ 25 years of accounting Experience

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity);
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable." Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

⁷ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Caren Currier certify that:

1. I have reviewed this Disclosure Statement for Lifeline BioTechnologies, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 15, 2026 [Date]

/s/Caren Currier [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Caren Currier certify that:

1. I have reviewed this Disclosure Statement for Lifeline BioTechnologies, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 15, 2026 [Date]

/s/Caren Currier [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

LIFELINE BIOTECHNOLOGIES, INC.
Balance Sheet Prev Year Comparison
As of March 31, 2026

	Mar 31, 26	Mar 31, 25
ASSETS		
Current Assets		
Checking/Savings	0.00	0.00
Accounts Receivable	0.00	0.00
Other Current Assets		
Inventory	0.00	0.00
Note Receivable	0.00	0.00
Prepaid Expenses	0.00	0.00
Total Other Current Assets	0.00	0.00
Total Current Assets	0.00	0.00
Fixed Assets	0.00	0.00
Other Assets	0.00	0.00
TOTAL ASSETS	0.00	0.00
LIABILITIES & EQUITY		
Liabilities		
Current Liabilities		
Accounts Payable	0.00	0.00
Credit Cards	0.00	0.00
Other Current Liabilities		
Accrued Expenses	8,500.00	6,000.00
Advances Payable	0.00	0.00
Due to Related Party - CC	50,041.00	25,236.50
Due to Related Party - SM	51,000.05	20,000.00
Payroll Liabilities	0.00	0.00
Total Other Current Liabilities	109,541.05	51,236.50
Total Current Liabilities	109,541.05	51,236.50
Long Term Liabilities	0.00	0.00
Total Liabilities	109,541.05	51,236.50
Equity		
Additional Paid in Capital	14,608,007.00	14,608,007.00
Capital Stock	0.00	0.00
Common Stock	34,489.00	34,489.00
Dividends Paid	0.00	0.00
Opening Balance Equity	0.00	0.00
Preferred Class A Stock	49.00	49.00
Preferred Class B	13.00	13.00
Retained Earnings	-14,752,099.05	-14,693,794.50
Total Equity	-109,541.05	-51,236.50
TOTAL LIABILITIES & EQUITY	0.00	0.00

LIFELINE BIOTECHNOLOGIES, INC.
Profit & Loss Prev Year Comparison
January through March 2026

	Jan - Mar 26	Jan - Mar 25
Ordinary Income/Expense		
Income	0.00	0.00
Expense		
Advertising and Promotion	0.00	0.00
Automobile Expense	0.00	0.00
Bank Service Charges	0.00	0.00
Business Licenses/Fees	0.00	0.00
Computer and Internet Expenses	0.00	0.00
Continuing Education	0.00	0.00
Depreciation Expense	0.00	0.00
Dues and Subscriptions	0.00	0.00
Insurance Expense	0.00	0.00
Interest Expense	0.00	0.00
Meals and Entertainment	0.00	0.00
Office Supplies	0.00	0.00
OTC Fees	0.00	0.00
Payroll Expenses	0.00	0.00
Professional Fees	0.00	0.00
Rent Expense	0.00	0.00
Repairs and Maintenance	0.00	0.00
Telephone Expense	0.00	0.00
Transfer Agent Fees	1,200.00	1,200.00
Travel Expense	0.00	0.00
Utilities	0.00	0.00
Total Expense	1,200.00	1,200.00
Net Ordinary Income	-1,200.00	-1,200.00
Other Income/Expense		
Other Income	0.00	0.00
Other Expense	0.00	0.00
Net Other Income	0.00	0.00
Net Income	-1,200.00	-1,200.00

LIFELINE BIOTECHNOLOGIES, INC.

Statement of Cash Flows

January through March 2026

	<u>Jan - Mar 26</u>	<u>Jan - Mar 26</u>
OPERATING ACTIVITIES		
Net Income	-1,200.00	-1,200.00
Adjustments to reconcile Net Income		
to net cash provided by operations:		
Inventory	0.00	0.00
Note Receivable	0.00	0.00
Prepaid Expenses	0.00	0.00
Accounts Payable	0.00	0.00
Accrued Expenses	200.00	1,200.00
Advances Payable	0.00	0.00
Due to Related Party - CC	0.00	0.00
Due to Related Party - SM	1,000.00	0.00
Payroll Liabilities	0.00	0.00
Net cash provided by Operating Activities	<u>0.00</u>	<u>0.00</u>
INVESTING ACTIVITIES		
Accumulated Depreciation	0.00	0.00
Furniture and Equipment	0.00	0.00
Deposits	0.00	0.00
Investments	0.00	0.00
Other Receivables	0.00	0.00
Net cash provided by Investing Activities	<u>0.00</u>	<u>0.00</u>
FINANCING ACTIVITIES		
Additional Paid in Capital	0.00	0.00
Capital Stock	0.00	0.00
Common Stock	0.00	0.00
Dividends Paid	0.00	0.00
Opening Balance Equity	0.00	0.00
Preferred Class A Stock	0.00	0.00
Preferred Class B	0.00	0.00
Retained Earnings	0.00	0.00
Net cash provided by Financing Activities	<u>0.00</u>	<u>0.00</u>
Net cash increase for period	0.00	0.00
Cash at beginning of period	0.00	0.00
Cash at end of period	<u><u>0.00</u></u>	<u><u>0.00</u></u>

Lifeline Biotechnologies, Inc.
Statements of Shareholders' Equity (Deficit)

	Preferred Shares	Amount	Common Stock Shares	Amount	Add'l Paid in Capital	Accumulated Deficit	Total
Balance at December 31, 2023	6,236,535	62	3,348,921,001	\$33,489	\$14,608,007	\$(14,686,794)	\$ (45,237)
Net Loss			1,000,000,000	\$ 1,000		\$ (5,800)	\$ (4,800)
Balance at December 31, 2024	6,236,535	62	4,348,921,001	\$34,489	\$14,608,007	\$(14,692,594)	\$ (50,037)
Net Loss						\$ (1,200)	\$ (1,200)
Balance at March 31, 2025	6,236,535	62	4,348,921,001	\$34,489	\$14,608,007	\$(14,693,794)	\$ (51,237)
Net Loss						\$ (25,777)	\$ (25,777)
Balance at June 30, 2025	6,236,535	62	4,348,921,001	\$34,489	\$14,608,007	\$(14,719,571)	\$ (77,014)
Net Loss						\$ (30,086)	\$ (30,086)
Balance at September 30, 2025	6,236,535	62	4,348,921,001	\$34,489	\$14,608,007	\$(14,749,658)	\$ (107,100)
Net Loss						\$ (1,241)	\$ (1,241)
Balance at December 31, 2025	6,236,535	62	4,348,921,001	\$34,489	\$14,608,007	\$(14,750,899)	\$ (108,341)
Net Loss						\$ (1,200)	\$ (1,200)
Balance at March 31, 2026	6,236,535	62	4,348,921,001	\$34,489	\$14,608,007	\$(14,752,099)	\$ (109,541)

LIFELINE BIOTECHNOLOGIES, INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
For The Period Ended March 31, 2026

NOTE 1: THE COMPANY AND THE SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of significant accounting policies followed in the preparation of these financial statements:

Organizational Information: LIFELINE BIOTECHNOLOGIES, INC. (the Company) was incorporated in 1981 in the State of Nevada.

Industry Information: Previous management was in the biotech/pharma field. The company is currently looking for a merger candidate.

Basis of Presentation: The accounting records of the Company are maintained on an accrual basis and the accompanying financial statements are presented on an accrual basis.

Depreciation and Amortization: The cost of property and equipment is depreciated over the estimated useful lives of the related assets using the accelerated recovery periods of the Internal Revenue Service. Purchased software is amortized on the straight-line basis over five years; organization expense and trademarks are amortized on the straight-line method over sixty months.

Accounts Receivable: The accounts receivable arise in the normal course of business of providing services to Customers. Accounts are written-off as they are deemed uncollectible based upon a periodic review of the accounts. At this time the company has no receivables.

Concentration of Credit Risk: Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits and trade accounts receivable. The Company has concentrated its credit risk for cash by maintaining deposits in financial institutions within the geographic region of Lincoln, Nebraska, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (FDIC). There are no excess deposit liabilities at this time. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk to cash. Concentrations of credit risk with respect to accounts receivable arise because the Company grants unsecured credit in the form of trade accounts receivable to its customers.

Management Estimations: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and

liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the period. Actual results could differ from those estimates. Principles of Consolidation: The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, LIFELINE BIOTECHNOLOGIES, INC. Inter-company transactions and balances have been eliminated in consolidation.

Cash and Equivalents: For purposes of reporting cash flows, the Company considers all cash accounts which are not subject to withdrawal restrictions or penalties, and certificates of deposit with original maturities of 90 days or less to be cash or cash equivalents.

Revenue Recognition: Revenues on subscription contracts are recognized monthly over the life of the contract. Amounts that have been invoiced are recorded in accounts receivable and revenue or deferred revenue, depending upon whether the revenue recognition criteria have been met.

Inventory: The Company maintains its inventory on a perpetual basis utilizing the first-in first-out (FIFO) method. There is no inventory at this time.

NOTE 2: GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has minimal working capital and net losses from inception. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required, and ultimately to attain profitability. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 3: INCOME TAX

The Company provides for income taxes under Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes. SFAS 109 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. SFAS 109 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Consequently, because of uncertainty about the Company's ability to realize any future tax benefits from its unused net operating losses, no deferred tax asset relating to those losses has been recorded.

NOTE 4: COMMITMENTS

The company has no leased space at this time

NOTE 5: NOTE PAYABLE

None

NOTE 6: CONSOLIDATION INFORMATION

None

NOTE 7: SHAREHOLDER NOTES PAYABLE

There is \$101,041 due to related parties for fees they have paid for company expenses

NOTE 8: LITIGATION

None

NOTE 9: OTHER EVENTS

Custodianship was terminated on July 1, 2024

NOTE 10: SUBSEQUENT EVENTS

None